A recent study published in Nature Medicine reveals that ubrogepant, a drug typically used for treating migraines, can also alleviate prior symptoms known as prodrome. These symptoms include fatigue, light sensitivity, and brain fog, which occur before a migraine escalates. Conducted over 60 days with 438 participants, the trial showed that ubrogepant effectively improved concentration and reduced anxiety from bright lights in some patients. However, notable effect sizes were found to be limited compared to a placebo, indicating further research is necessary for definitive applications.
The findings indicate that ubrogepant can significantly alleviate migraine prodrome symptoms like fatigue and light sensitivity, offering patients relief before the headache starts.
Despite showing potential to help with early migraine symptoms, the effectiveness of ubrogepant was limited, with improvements noted only as small effect sizes compared to placebo.
Collection
[
|
...
]